American Society of Clinical Oncology: Targeted Agent & Profiling Utilization Registry Study Shows Encouraging Results for Olaparib
May 30, 2020
May 30, 2020
ALEXANDRIA, Virginia, May 30 -- The American Society of Clinical Oncology issued the following news release on May 29:
Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations. The findings will be presented as part of the virtu . . .
Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations. The findings will be presented as part of the virtu . . .